Cart
sales@molnova.com
N-(4-bromo-2-chlorophenyl)-5-chloro-2-hydroxybenzamide
CAS No. 1098360-68-9
N-(4-bromo-2-chlorophenyl)-5-chloro-2-hydroxybenzamide( —— )
Catalog No. M28422 CAS No. 1098360-68-9
N-(4-bromo-2-chlorophenyl)-5-chloro-2-hydroxybenzamide is a chemical compound.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 113 | Get Quote |
|
| 5MG | 174 | Get Quote |
|
| 10MG | 262 | Get Quote |
|
| 25MG | 447 | Get Quote |
|
| 50MG | 651 | Get Quote |
|
| 100MG | 888 | Get Quote |
|
| 500MG | 1782 | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameN-(4-bromo-2-chlorophenyl)-5-chloro-2-hydroxybenzamide
-
NoteResearch use only, not for human use.
-
Brief DescriptionN-(4-bromo-2-chlorophenyl)-5-chloro-2-hydroxybenzamide is a chemical compound.
-
DescriptionN-(4-bromo-2-chlorophenyl)-5-chloro-2-hydroxybenzamide is a chemical compound.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
Recptorapolipoprotein L1
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1098360-68-9
-
Formula Weight361.02
-
Molecular FormulaC13H8BrCl2NO2
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESOc1ccc(Cl)cc1C(=O)Nc1ccc(Br)cc1Cl
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
LDN-193189 2HCl
LDN-193189 2HCl (DM-3189 2HCl) is a selective BMP signaling inhibitor that inhibits ALK1,ALK2,ALK3 and ALK6, showing IC50s of 0.8 nM, 0.8 nM, 5.3 nM, and 16.7 nM, respectively, in kinase assays.
-
Neocryptotanshinone
Neocryptotanshinone inhibits rabbit platelet aggregation induced by arachidonic acid.
-
Syk Inhibitor II hyd...
The impact of spleen tyrosine kinase (Syk) signaling might be prominent in lupus because (i) Syk is a shared downstream signaling molecule among circulating immune complex, LPS, and (1→3)-β-D-glucan (BG), and (ii) all of these factors are detectable in the serum of Fc gamma receptor IIb-deficient (FcgRIIb-/-) mice with sepsis. Syk inhibition downregulated several inflammatory pathways in FcgRIIb-/- macrophages activated with BG + LPS suggesting the potential anti-inflammatory impact of Syk inhibitors in lupus.
